Swedish Cystic Fibrosis Patient Registry (Sweden) **
For questions relating to research purposes, or when planning research projects to reconcile variables, time periods and data access, etc., contact the data controller:
Anders Lindblad, MD
Queen Silvia Childrens Hospital
416 85 Gothenburg
SWEDEN
Phone: +46 31 343 4336
Email: anders.lindblad@vgregion.se
If you cannot reach the database manager, you may contact the Swedish Cystic Fibrosis Registry by completing the contact form at: https://www.cf-registret.se/kontakt
Link to application form for data from the CF register for research purposes:
https://cf-registret.se/onewebmedia/Formula%CC%88r_Registeruppg.pdf
1. Nilsson M. P325 Nutritional status with specific focus in fat soluble vitamins in Swedish patients with cystic fibrosis–a registry study. Journal of Cystic Fibrosis. 2025 Jun 1;24:S169.
2. Svedberg M, Holmberg L, Imberg H. P123 Evaluating pulmonologists' accuracy in visually estimating lung function trends in cystic fibrosis. Journal of Cystic Fibrosis. 2025 Jun 1;24:S105.
3. Krantz C. WS13. 06Absence of neonatal screening for cystic fibrosis in Sweden causes delay in effective treatment. Journal of Cystic Fibrosis. 2025 Jun 1;24:S27.
4. Svedberg M, Hagel E, Kranz C, Imberg H. P112 Real-time estimation of individual long-and short-term lung functions trends in persons with cystic fibrosis within the Swedish cystic fibrosis registry. Journal of Cystic Fibrosis. 2024 Jun 1;23:S119.
5. Al Shakirchi M, Sorjonen K, Hjelte L, Klingspor L, Bergman P, Ericson P, Svedberg M, Lindberg U, Hansen C, Monestrol ID. Impact of lumacaftor/ivacaftor on the bacterial and fungal respiratory pathogens in cystic fibrosis: A prospective multicenter cohort study in Sweden. Therapeutic Advances in Respiratory Disease. 2024 May;18:17534666241254090.
6. Lindblad A, Monestrol I, Gilljam M, Krantz C, McGarry LJ, Banefelt J, Aldvén M. Clinical, economic, and societal burden of cystic fibrosis and the impact of the CFTR modulator, lumacaftor/ivacaftor: an assessment using linked registry data in Sweden. J Med Econ. 2024 Jan-Dec;27(1):897-906.
7. Svedberg M, Imberg H, Gustafsson PM, Tiddens H, Davies G, Lindblad A. Longitudinal lung clearance index and association with structural lung damage in children with cystic fibrosis. Thorax. 2023 Feb;78(2):176-182.
8. Kowalik A, de Monestrol I, Sorjonen K, Brockow K, Gülen T. Antibiotic hypersensitivity in cystic fibrosis - Low frequency of anaphylaxis over 16 000 courses. Br J Clin Pharmacol. 2022 Nov;88(11):4845-4853.
9. Blomquist A, Inghammar M, Al Shakirchi M, Ericson P, Krantz C, Svedberg M, Lindblad A, Påhlman LI. Persistent Aspergillus fumigatus infection in cystic fibrosis: impact on lung function and role of treatment of asymptomatic colonization-a registry-based case-control study. BMC Pulm Med. 2022 Jul 5;22(1):263.
10. Hortal CR, Wilhelmsson S, Törnberg A, Lannefors L, Hoel L, Ersson K, Dennersten-Kvist U, Wallin K, Mårtensson M, Hedborg A. WS16. 6 Decreased performance of airway clearance and physical exercise with age in the Swedish cystic fibrosis population-what’s the solution?. Journal of Cystic Fibrosis. 2020 Jun 1;19:S28.